Document is current

Article History

Received: 10 April 2024

Accepted: 27 June 2024

First Online: 5 July 2024

Declarations

:

: Data was carried out according to the Spanish Order SAS/3470/2009, from December 16th, which publishes the guidelines for observational studies, and the Law 14/2007, of July 3rd, on Biomedical Research. Data were recorded following Good Clinical Practice compliance at each hospital, respecting the Regulation (EU) 2016/679 of the European Parliament and the Council of April 27th of 2016 on data protection.

: Not applicable.

: PEG has received advisory/consultancy honoraria from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro and PharmaMar; speaker bureau/expert testimony honoraria from AstraZeneca-MSD, PharmaMar, Roche, GSK-Tesaro and Clovis; and travel/accommodation/expenses from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro and PharmaMar. BHFA has received Advisory Board honoraria from GSK-Tesaro, Seagen, Pierre Fabre and Clovis; Speaking Bureau honoraria from Pharmamar, Pfizer, Lilly, Daiichi Sankyo and Pierre Fabre; and Institutional Grants from MSD, Novartis, GSK and Roche. EMGA has received advisory/consultancy honoraria from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro, PharmaMar and Roche; speaker bureau/expert testimony honoraria from AstraZeneca-MSD, PharmaMar, Roche, GSK-Tesaro and Clovis; and travel/accommodation/expenses from Roche, GSK-Tesaro and Baxter. IR has received Advisory Board honoraria from Astra Zeneca, GSK, MSD, Clovis and Pharmamar; Speaking Bureau honoraria from Roche, GSK, MSD and Astra Zeneca; Institutional Grants from GSK, Roche and Astra Zeneca; and travel grants from Astra Zeneca, MSD, GSK and EISAI. AGM declares receiving advisory/consultancy honoraria from Alkermes, Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, Macrogenmics, Novartis, Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio and Sutro; Speaker Bureau honoraria from AstraZeneca, PharmaMar, Roche, GSK and Clovis; Research grants and/or funding from Roche and TESARO: A GSK Company; and travel and accommodations expenses from AstraZeneca, Pharmamar Roche and TESARO: A GSK Company. The rest of the authors have nothing to declare.